<DOC>
	<DOCNO>NCT00004164</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient stage IIB , stage III , stage IV cancer nasopharynx .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage IIB , Stage III , Stage IV Cancer Nasopharynx</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete overall response rate docetaxel , cisplatin , fluorouracil , leucovorin calcium patient potentially curable nasopharyngeal cancer . II . Assess tolerability regimen patient . OUTLINE : Patients receive docetaxel IV 1 hour follow 1 hour later cisplatin IV 4 hour fluorouracil IV leucovorin calcium IV 96 hour . Filgrastim ( G-CSF ) administer subcutaneously begin day 5 continue blood count recover day 10 . Treatment repeat every 3 week 3 course . Within 2 week completion chemotherapy , patient undergo definitive radiotherapy 7 week . After radiotherapy , patient achieve complete remission chemotherapy may undergo surgery . Patients follow monthly 1 year , every 3 month thereafter . PROJECTED ACCRUAL : A total 45 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , previously untreated stage IIB , III , IV carcinoma nasopharynx Metastatic disease must limit site amenable curative irradiation surgical resection Locally recurrent disease surgery allow Evaluable disease No prior head neck cancer , unless treat solely surgery PATIENT CHARACTERISTICS : Age : Any age Performance status : ECOG 02 Life expectancy : Greater 3 month Hematopoietic : WBC least 3000/mm3 OR Absolute neutrophil count least 1000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT/SGPT great 1.5 time ULN ( great 2.5 time ULN alkaline phosphatase great ULN ) Alkaline phosphatase great 2.5 time ULN ( great 4 time ULN SGOT/SGPT great ULN ) Alkaline phosphatase ULN know bony invasion present hepatic enzyme normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : No significant cardiovascular disease Pulmonary : No significant pulmonary disease Other : No concurrent prior malignancy within past 3 year except limited basal cell squamous cell skin cancer carcinoma situ cervix No grade 2 bad peripheral neuropathy No serious illness medical condition Adequate nutritionally balance enteral intake No requirement intravenous alimentation primary source calorie Able tolerate 34 liter IV saline per day Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy nasopharyngeal cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy nasopharyngeal cancer Surgery : See Disease Characteristics Recovered prior surgery Other : Recovered prior diagnostic therapeutic procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2000</verification_date>
	<keyword>stage II nasopharyngeal cancer</keyword>
	<keyword>stage III nasopharyngeal cancer</keyword>
	<keyword>stage IV nasopharyngeal cancer</keyword>
</DOC>